Literature DB >> 23322741

Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis.

Matthew T James1, Susan M Samuel, Megan A Manning, Marcello Tonelli, William A Ghali, Peter Faris, Merril L Knudtson, Neesh Pannu, Brenda R Hemmelgarn.   

Abstract

BACKGROUND: Contrast-induced acute kidney injury (CI-AKI) has been associated with mortality, although it has been suggested this association may be attributable to confounding. We performed a systematic review and meta-analysis to characterize the associations between CI-AKI and subsequent clinical outcomes. METHODS AND
RESULTS: We identified studies using MEDLINE (1950 to June 2011) and Embase (1980 to June 2011), manual bibliographic searches, and contact with experts. We included observational studies that characterized outcomes among patients with and without AKI (based on changes in serum creatinine) after coronary angiography. Eligible studies reported at least 1 of mortality, cardiovascular events, end-stage renal disease, or length of hospital stay. Thirty-nine observational studies met inclusion criteria. Of 34 studies reporting mortality (including 139 603 participants), 33 reported an increased risk of death in those with CI-AKI, although the effect size varied between studies (I(2)=93.5%). Between-study heterogeneity was partially explained by whether adjustment for confounding features was performed (11 studies without adjustment; pooled crude risk ratio, 8.19; 95% confidence interval, 4.30-15.60; I(2)=77.3% versus 23 studies with adjustment; pooled adjusted risk ratio, 2.39; 95% confidence interval, 1.98-2.90; I(2)=88.3%). CI-AKI was consistently associated with an increased risk of cardiovascular events in 14 studies, end-stage renal disease in 3 studies, and prolonged hospitalization in 11 studies.
CONCLUSIONS: CI-AKI is associated with an increased risk of mortality, cardiovascular events, renal failure, and prolonged hospitalization. However, the association between CI-AKI and mortality is strongly confounded by baseline clinical characteristics that simultaneously predispose to both kidney injury and mortality, and the risk attributable to CI-AKI is much lower than that reported from unadjusted studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23322741     DOI: 10.1161/CIRCINTERVENTIONS.112.974493

Source DB:  PubMed          Journal:  Circ Cardiovasc Interv        ISSN: 1941-7640            Impact factor:   6.546


  79 in total

1.  Acute kidney injury based on the KDIGO criteria among ST elevation myocardial infarction patients treated by primary percutaneous intervention.

Authors:  Gilad Margolis; Amir Gal-Oz; Sevan Letourneau-Shesaf; Shafik Khoury; Gad Keren; Yacov Shacham
Journal:  J Nephrol       Date:  2017-11-28       Impact factor: 3.902

Review 2.  Optical coherence tomography-guided percutaneous coronary intervention: a review of current clinical applications.

Authors:  Kazumasa Kurogi; Masanobu Ishii; Nobuyasu Yamamoto; Kenshi Yamanaga; Kenichi Tsujita
Journal:  Cardiovasc Interv Ther       Date:  2021-01-17

3.  No prophylaxis is non-inferior and cost-saving to prophylactic intravenous hydration in preventing contrast-induced nephropathy on requiring iodinated contrast material administration.

Authors:  Akira Sato; Tomoya Hoshi; Kazutaka Aonuma
Journal:  J Thorac Dis       Date:  2017-06       Impact factor: 2.895

4.  Guideline on the use of iodinated contrast media in patients with kidney disease 2018.

Authors:  Yoshitaka Isaka; Hiromitsu Hayashi; Kazutaka Aonuma; Masaru Horio; Yoshio Terada; Kent Doi; Yoshihide Fujigaki; Hideo Yasuda; Taichi Sato; Tomoyuki Fujikura; Ryohei Kuwatsuru; Hiroshi Toei; Ryusuke Murakami; Yoshihiko Saito; Atsushi Hirayama; Toyoaki Murohara; Akira Sato; Hideki Ishii; Tadateru Takayama; Makoto Watanabe; Kazuo Awai; Seitaro Oda; Takamichi Murakami; Yukinobu Yagyu; Nobuhiko Joki; Yasuhiro Komatsu; Takamasa Miyauchi; Yugo Ito; Ryo Miyazawa; Yoshihiko Kanno; Tomonari Ogawa; Hiroki Hayashi; Eri Koshi; Tomoki Kosugi; Yoshinari Yasuda
Journal:  Clin Exp Nephrol       Date:  2020-01       Impact factor: 2.801

5.  Effect of Contrast-Induced Nephropathy on the Long-Term Outcome of Patients with Non-ST Segment Elevation Myocardial Infarction.

Authors:  Burak Turan; Ayhan Erkol; Mehmet Gül; Uğur Fındıkçıoğlu; İsmail Erden
Journal:  Cardiorenal Med       Date:  2015-02-28       Impact factor: 2.041

6.  Relationship of Kidney Injury Biomarkers with Long-Term Cardiovascular Outcomes after Cardiac Surgery.

Authors:  Chirag R Parikh; Jeremy Puthumana; Michael G Shlipak; Jay L Koyner; Heather Thiessen-Philbrook; Eric McArthur; Kathleen Kerr; Peter Kavsak; Richard P Whitlock; Amit X Garg; Steven G Coca
Journal:  J Am Soc Nephrol       Date:  2017-08-14       Impact factor: 10.121

7.  Cardiovascular events after AKI: a new dimension.

Authors:  Chi-Yuan Hsu; Kathleen D Liu
Journal:  J Am Soc Nephrol       Date:  2014-02-06       Impact factor: 10.121

8.  Renal impairment according to acute kidney injury network criteria among ST elevation myocardial infarction patients undergoing primary percutaneous intervention: a retrospective observational study.

Authors:  Yacov Shacham; Eran Leshem-Rubinow; Arie Steinvil; Eyal Ben Assa; Gad Keren; Arie Roth; Yaron Arbel
Journal:  Clin Res Cardiol       Date:  2014-02-13       Impact factor: 5.460

9.  High sensitive C-reactive protein and the risk of acute kidney injury among ST elevation myocardial infarction patients undergoing primary percutaneous intervention.

Authors:  Yacov Shacham; Eran Leshem-Rubinow; Arie Steinvil; Gad Keren; Arie Roth; Yaron Arbel
Journal:  Clin Exp Nephrol       Date:  2014-12-10       Impact factor: 2.801

10.  Brain natriuretic peptide for prevention of contrast-inducednephropathy: a meta-analysis of randomized controlled trials.

Authors:  Xue-Biao Wei; Lei Jiang; Xin-Rong Liu; Dan-Qing Yu; Ning Tan; Ji-Yan Chen; Ying-Ling Zhou; Peng-Cheng He; Yuan-Hui Liu
Journal:  Eur J Clin Pharmacol       Date:  2016-10-01       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.